- Home
- IRON vs SOC Comparison
IRON vs SOC Comparison
Compare IRON & SOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- SOC
- Stock Information
- Founded
- IRON 2017
- SOC 2020
- Country
- IRON United States
- SOC United States
- Employees
- IRON N/A
- SOC N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- SOC
- Sector
- IRON Health Care
- SOC
- Exchange
- IRON Nasdaq
- SOC Nasdaq
- Market Cap
- IRON 2.1B
- SOC 2.0B
- IPO Year
- IRON N/A
- SOC N/A
- Fundamental
- Price
- IRON $67.78
- SOC $19.10
- Analyst Decision
- IRON Strong Buy
- SOC Buy
- Analyst Count
- IRON 10
- SOC 3
- Target Price
- IRON $97.80
- SOC $30.00
- AVG Volume (30 Days)
- IRON 380.9K
- SOC 5.9M
- Earning Date
- IRON 11-11-2025
- SOC 11-13-2025
- Dividend Yield
- IRON N/A
- SOC N/A
- EPS Growth
- IRON N/A
- SOC N/A
- EPS
- IRON N/A
- SOC N/A
- Revenue
- IRON N/A
- SOC N/A
- Revenue This Year
- IRON N/A
- SOC N/A
- Revenue Next Year
- IRON N/A
- SOC $184.34
- P/E Ratio
- IRON N/A
- SOC N/A
- Revenue Growth
- IRON N/A
- SOC N/A
- 52 Week Low
- IRON $30.82
- SOC $16.26
- 52 Week High
- IRON $68.79
- SOC $35.00
- Technical
- Relative Strength Index (RSI)
- IRON 69.97
- SOC 38.61
- Support Level
- IRON $65.26
- SOC $17.25
- Resistance Level
- IRON $68.79
- SOC $20.32
- Average True Range (ATR)
- IRON 2.67
- SOC 1.83
- MACD
- IRON 0.53
- SOC -0.21
- Stochastic Oscillator
- IRON 88.97
- SOC 23.99
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California. The company is managed as one reportable segment, oil and gas.